ClinicalTrials.gg
CompletedNCT01000974Updated Jul 12, 2018Results posted

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

A Phase 3 interventional study of GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108) and ActHIB™ in Haemophilus Influenzae Type b, sponsored by GlaxoSmithKline. Completed at 63 sites in United States. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,003
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
6th of 80
4,003 · median 445
Started
2010
with 7 others
Phase 3
48 of 82
none open now
Registered
52nd of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 6th largest by enrollment of the 80 interventional ones that give a count, is one of 8 that started in 2010, is one of 48 in phase 3, and was the 52nd registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate vaccine and the licensed monovalent Hib vaccine ActHIB as well as the licensed combination product Pentacel in infants at 2, 4, 6 and 15-18 months of age. This study is designed with a primary and a booster phase.

Read the detailed description

This protocol posting has been updated following protocol amendment 3, dated 12 April 2011. The impacted section is: Eligibility Criteria (Exclusion criteria).

03

Conditions studied

  • Haemophilus Influenzae Type b

Keywords

  • primary vaccination course
  • Haemophilus influenzae type b
  • infants, children
  • booster vaccination
  • immunogenicity
  • safety
  • Gram-negative bacterial infections
  • vaccines, conjugate
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects for whom the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR[s]) can and will comply with the requirements of the protocol (e.g., completion of the diary card, return for follow-up visits).
  • A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
  • Written obtained from the subject's parent/LAR.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Born after a gestation period of minimum 36 weeks.
  • Infants who have not received a previous dose of vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs since birth.
  • Planned administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine and until 30 days after the booster dose.
  • Previous vaccination against Haemophilus influenzae type b, diphtheria, tetanus, pertussis, Pneumococcus, rotavirus and/or poliovirus; more than one previous dose of vaccine.
  • History of Haemophilus influenzae type b, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus, and hepatitis B diseases.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including dry natural latex rubber.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • Acute disease at time of enrollment. All vaccines can be administered to persons with a minor illness.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Concurrent participation in another clinical study, up to 30 days prior to study entry or at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Child in care.
  • History of intussusception.
  • History of uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.
  • History of Severe Combined Immunodeficiency Disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
4,003 participants (actual)

Study arms

  • Experimental
    Hiberix Group

    Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.

    Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108) · Biological: Pediarix™ · Biological: Prevnar 13™ · Biological: Rotarix™ · Biological: Infanrix™

  • Active comparator
    ActHIB Group

    Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.

    Biological: ActHIB™ · Biological: Pediarix™ · Biological: Prevnar 13™ · Biological: Rotarix™ · Biological: Infanrix™

  • Active comparator
    Pentacel Group

    Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.

    Biological: Pentacel™ · Biological: Prevnar 13™ · Biological: Rotarix™ · Biological: Engerix™-B

Interventions

  • Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.

    Also known as: Hiberix®

  • BiologicalActHIB™

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination

  • BiologicalPentacel™

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination

  • BiologicalPediarix™

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

  • BiologicalPrevnar 13™

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

  • BiologicalRotarix™

    Two oral doses in primary epoch at 2 and 4 months of age

  • BiologicalEngerix™-B

    Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection

  • BiologicalInfanrix™

    One dose in the booster epoch at 15-18 months of age as intramuscular injection

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL

    Non-inferiority of Hiberix to ActHIB, each co-administered with Pediarix, Prevnar13 and Rotarix following 3 primary doses in terms of immune response to PRP (Anti-PRP≥ 0.15 µ g/ml and ≥1.0 µg/mL).

    Time frame: At 1 month after last dose of primary vaccination

  2. Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)

    Non-inferiority of Pediarix co-administered with Hiberix, Prevnar13 and Rotarix compared to Pediarix co-administered with ActHIB, Prevnar13 and Rotarix following 3 primary vaccine doses in terms of immune response to Diphtheria, Tetanus.

    Time frame: At 1 month after last dose of primary vaccination

  3. Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations

    Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).

    Time frame: At 1 month after last dose of primary vaccination

  4. Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody Concentrations

    Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.

    Time frame: At 1 month after last dose of primary vaccination

  5. Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody Concentrations

    Antibody concentrations against S.pneumoniae were given as geometric mean concentrations (GMCs) expressed as microgram per milliliter (µg/mL).

    Time frame: At 1 month after last dose of primary vaccination

  6. Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)

    Seroresponse (95%) was defined as the number of subjects showing a concentration above a threshold that leads to 95% seroresponse in the ActHIB group.

    Time frame: At 1 month after last dose of primary vaccination

  7. Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off Value

    The cut-off value was defined as a concentration ≥ 8 ED50 (ED50 is the concentration at which the protein exhibits 50% of its maximum activity). The polio testing which started at the Biomnis laboratory was stopped because the polio virus micro-neutralization assays were found to be not in line with the quality standards defined in GSK Biologicals' SOPs. As a result, polio testing was restarted at the GSK laboratory and the results were uploaded into the clinical database.

    Time frame: At 1 month after last dose of primary vaccination

  8. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL

    Non-inferiority of a booster dose of Hiberix co-administered with Infanrix in subjects 15-18 months of age who received 3 primary vaccine doses of Hiberix to a booster dose of ActHIB co-administered with Infanrix in subjects of 15-18 months of age who received 3 primary vaccine doses of ActHIB in terms of immune response to PRP

    Time frame: At 1 month after booster vaccination

Secondary outcomes

  1. Anti-protein-D (Anti-D) and Anti-protein-T (Anti-T) Antibody Concentrations

    Antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as International Units per milliliter (IU/mL).

    Time frame: At 1 month after last dose of primary vaccination

  2. Number of Subjects With Any Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.

    Time frame: During a 4-day follow-up period (Days 0-3) following any vaccination

  3. Number of Subjects With Any Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Rectal temperature equal to or above (≥) 38 degrees Celsius (°C).

    Time frame: During a 4-day follow-up period (Days 0-3) following any vaccination

  4. Number of Subjects With Any Unsolicited Adverse Events (AEs).

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day (Day 0-Day 30) follow-up period after primary vaccination

  5. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Day 0 until 6 months following the last primary dose

  6. Number of Subjects With AEs of Specific Interest (AESIs)

    An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.

    Time frame: From Day 0 until 6 months following the last primary dose or the receipt of the booster vaccination, whichever comes first

  7. Number of Subjects With Seroresponse (90%) to Anti-PT, Anti-PRN and Anti-FHA

    Seroresponse (90%) was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.

    Time frame: At 1 month after last dose of primary vaccination

  8. Number of Subjects With Anti-PT, Anti-PRN and Anti-FHA Antibody Concentrations ≥ 5 EL.U/mL

    Seroresponse was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.

    Time frame: At 1 month after last dose of primary vaccination

  9. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL

    Evaluation of persistence of anti-PRP antibodies induced by three primary vaccine doses of Hiberix, and ActHIB, each co-administered with Pediarix, Prevnar 13 and Rotarix, or Pentacel co-administered with Engerix-B, Rotarix and Prevnar 13 prior to the booster dose of Hiberix, ActHIB or Pentacel at 15-18 months of age and evaluation of immunogenicity of a booster dose of Hiberix co-administered with Infanrix, ActHIB co-administered with Infanrix and Pentacel in terms of the percentage of subjects with anti-PRP concentrations ≥0.15 µg/mL, ≥1.0 µg/mL and GMCs one month after the booster dose.

    Time frame: Prior to the booster vaccination and 1 month after the booster vaccination

  10. Anti-Hepatitis B (Anti-HBs) Antibody Concentrations

    Antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressedas milli-international units per milliliter (mIU/mL).

    Time frame: At 1 month after last dose of primary vaccination

  11. Number of Subjects With S.Pneumoniae Antibody Concentrations ≥ 0.05 µg/mL, ≥ 0.2 µg/mL and ≥1.0 µg/mL

    Evaluation of immunogenicity of a 3-dose primary vaccination course of Prevnar 13 co-administered with Hiberix, Rotarix and Pediarix, of Prevnar 13 co-administered with ActHIB, Rotarix and Pediarix and of Prevnar 13 co-administered with Pentacel, Rotarix and Engerix-B in terms of S.pneumoniae GMCs and antibody concentrations ≥ 0.05µg/mL, ≥ 0.2 µg/mL, ≥ 1.0 µg/mL at one month after the last dose of primary vaccination.

    Time frame: At 1 month after the last dose of primary vaccination

  12. Antibody Titers for Poliovirus Types 1, 2 and 3

    Antibody titers were given as geometric mean titers(GMTs).

    Time frame: At 1 month after last dose of primary vaccination

  13. Number of Subjects With Anti-HBs Antibody Concentrations Greater Than or Equal to Cut-off Values

    The cut-off values were defined as a concentration≥ 3.3 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).

    Time frame: At 1 month after last dose of primary vaccination

  14. Anti-polyribosylribitol Phosphate (PRP) Antibody Concentrations

    Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).

    Time frame: Prior to the booster vaccination and 1 month after the booster vaccination

  15. Anti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL

    Antibody concentrations were expressed as geometric mean concentrations (GMCs) and expressed as milli-international units per milliliter (mIU/mL).

    Time frame: Prior to the booster vaccination

  16. Number of Subjects With Anti-HB Antibody Concentrations ≥10.0 mlU/mL and ≥6.2mLU/mL

    The cut-off values were defined as a concentration≥ 6.2 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).

    Time frame: Prior to booster vaccination

  17. Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations ≥ 5 EL.U/mL

    Evaluation of persistence of anti-PT, anti-FHA and anti-PRN antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-PT, anti-FHA and anti- PRN antibodies.

    Time frame: Prior to the booster vaccination and 1 month after the booster vaccination

  18. Anti-poliovirus Types 1, 2, and 3 Antibody Titres and Titres ≥ 8

    Antibody concentrations were tabulated as geometric mean titers (GMTs) and expressed as titers.

    Time frame: Prior to the booster vaccination

  19. Number of Subjects With Anti-Polio-1,2,3 Antibody Titers ≥ 8

    Anti-polio 1,2,3 antibody titers greater or equal to the cut off value were calculated.

    Time frame: Prior to booster vaccination

  20. Number of Subjects With Anti-D and Anti-T Antibody Concentrations ≥ 0.1 IU/mL and ≥1.0 IU/mL, Respectively.

    Evaluation of persistence of anti-D, anti-T antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-D and anti-T antibodies.

    Time frame: Prior to the booster vaccination and 1 month after the booster vaccination

  21. Number of Subjects With Any Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.

    Time frame: Within 4 days (Days 0-3) following the booster dose

  22. Number of Subjects With Any Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Axillary temperature equal to or above (≥) 38 degrees Celsius (°C).

    Time frame: Within 4 days (Days 0-3) following the booster dose

  23. Number of Subjects With AEs of Specific Interest (AESIs)

    An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.

    Time frame: From booster dose until 6 months following receipt of the booster dose

  24. Number of Subjects With Any Unsolicited Adverse Events (AEs).

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: Within 31 days (Day 0 to Day 30) following the booster dose

  25. Number of Subjects With Serious Adverse Events (SAEs)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From the booster dose until 6 months following receipt of the booster dose

  26. Anti-FHA, Anti-PRN and Anti-PT Antibody Concentrations

    Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.

    Time frame: pre-booster and one month after booster vaccination

07

Results

Posted Aug 19, 2013
Limitations and caveats
Anti-HBs antibody concentration cut off defining seropositivity was based on 6.2 mIU/mL instead of 3.3 mIU/mL for the pre-booster vaccination phase as tested by the commercial assay Centaur

Participant flow

Primary Vaccination Phase
Participant flow — Primary Vaccination Phase
MilestoneHiberix GroupActHIB GroupPentacel Group
Started2963520520
Completed2625470457
Not completed3385063
Withdrew: Withdrawal by subject1091721
Withdrew: Lost to follow-up1711926
Withdrew: Protocol violation4032
Withdrew: Adverse event1422
Withdrew: Other4912
Booster Vaccination Phase
Participant flow — Booster Vaccination Phase
MilestoneHiberix GroupActHIB GroupPentacel Group
Started2337435400
Completed2270423386
Not completed671214
Withdrew: Protocol violation002
Withdrew: Withdrawal by subject311
Withdrew: Lost to follow-up4057
Withdrew: Other2464

Outcome measures

PrimaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL

Non-inferiority of Hiberix to ActHIB, each co-administered with Pediarix, Prevnar13 and Rotarix following 3 primary doses in terms of immune response to PRP (Anti-PRP≥ 0.15 µ g/ml and ≥1.0 µg/mL).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-PRP ≥ 0.15 µg/mL1536265234
Anti-PRP ≥ 1.0 µg/mL1291246198
Statistical analysis
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: -8.59 · 95% CI -12.28 to -4.07
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: -0.11 · 95% CI -1.98 to 2.82
PrimaryNumber of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)

Non-inferiority of Pediarix co-administered with Hiberix, Prevnar13 and Rotarix compared to Pediarix co-administered with ActHIB, Prevnar13 and Rotarix following 3 primary vaccine doses in terms of immune response to Diphtheria, Tetanus.

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-D393273249
Anti-T393274249
Statistical analysis
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: 0 · 95% CI -1.26 to 1.81
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: 0 · 95% CI -1.26 to 1.8
PrimaryAnti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations

Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Geometric mean · µg/mL
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
µg/mLHiberix GroupActHIB GroupPentacel Group
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations5.193 (4.765 to 5.658)6.743 (5.593 to 8.129)3.640 (2.891 to 4.583)
PrimaryAnti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody Concentrations

Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Geometric mean · EL.U/mL
Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody Concentrations
EL.U/mLHiberix GroupActHIB GroupPentacel Group
Anti-PT73.2 (69.8 to 76.6)71.9 (66.6 to 77.6)41.9 (38.4 to 45.8)
Anti-PRN111.6 (104.5 to 119.2)93.5 (83.7 to 104.4)51.9 (45.4 to 59.3)
Anti-FHA321.8 (307.0 to 337.3)295.8 (276.0 to 317.0)174.8 (160.0 to 191.0)
Statistical analysis
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.017 · 97.5% CI 0.918 to 1.127
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.088 · 97.5% CI 0.983 to 1.204
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.193 · 97.5% CI 1.03 to 1.382
PrimaryAnti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody Concentrations

Antibody concentrations against S.pneumoniae were given as geometric mean concentrations (GMCs) expressed as microgram per milliliter (µg/mL).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Geometric mean · µg/mL
Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody Concentrations
µg/mLHiberix GroupActHIB GroupPentacel Group
Anti-Pneumoniae 12.515 (2.318 to 2.729)2.500 (2.278 to 2.745)2.442 (2.190 to 2.722)
Anti-Pneumoniae 31.056 (0.976 to 1.142)1.008 (0.933 to 1.089)1.190 (1.066 to 1.329)
Anti-Pneumoniae 41.804 (1.684 to 1.932)1.803 (1.662 to 1.957)1.819 (1.645 to 2.011)
Anti-Pneumoniae 53.729 (3.409 to 4.079)3.656 (3.308 to 4.040)3.530 (3.128 to 3.984)
Anti-Pneumoniae 6A3.442 (3.177 to 3.729)3.340 (3.032 to 3.679)3.384 (3.046 to 3.760)
Anti-Pneumoniae 6B1.065 (0.950 to 1.196)0.994 (0.860 to 1.148)0.875 (0.757 to 1.013)
Anti-Pneumoniae 7F4.518 (4.192 to 4.870)4.115 (3.777 to 4.484)3.785 (3.412 to 4.199)
Anti-Pneumoniae 9V2.516 (2.305 to 2.746)2.431 (2.204 to 2.681)2.226 (1.976 to 2.507)
Anti-Pneumoniae 144.506 (4.105 to 4.946)4.111 (3.672 to 4.602)3.938 (3.472 to 4.466)
Anti-Pneumoniae 18C3.655 (3.351 to 3.986)3.507 (3.196 to 3.848)3.401 (3.033 to 3.814)
Anti-Pneumoniae 19A1.556 (1.433 to 1.689)1.553 (1.391 to 1.735)1.321 (1.175 to 1.486)
Anti-Pneumoniae 19F2.745 (2.552 to 2.952)2.833 (2.613 to 3.072)2.531 (2.315 to 2.766)
Anti-Pneumoniae 23F2.046 (1.846 to 2.267)1.985 (1.765 to 2.232)1.670 (1.444 to 1.931)
Statistical analysis
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.006 · 97.5% CI 0.873 to 1.159
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.048 · 97.5% CI 0.921 to 1.192
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.001 · 97.5% CI 0.886 to 1.13
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.02 · 97.5% CI 0.874 to 1.19
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.031 · 97.5% CI 0.894 to 1.188
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.072 · 97.5% CI 0.871 to 1.32
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.098 · 97.5% CI 0.964 to 1.251
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.035 · 97.5% CI 0.89 to 1.204
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.096 · 97.5% CI 0.929 to 1.294
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.042 · 97.5% CI 0.9 to 1.207
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.001 · 97.5% CI 0.859 to 1.167
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 0.969 · 97.5% CI 0.855 to 1.098
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Gmc ratio: 1.031 · 97.5% CI 0.862 to 1.232
PrimaryNumber of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)

Seroresponse (95%) was defined as the number of subjects showing a concentration above a threshold that leads to 95% seroresponse in the ActHIB group.

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-PT764264201
Anti-PRN762262213
Anti-FHA744263191
Statistical analysis
  • Hiberix Group vs ActHIB Group · t-test, 1 sided · p = <0.0001P-value is computed by integrating on the p-values of one-sided test with alpha=0.025 \& the posterior probability of the cut-off in the control group
  • Hiberix Group vs ActHIB Group · t-test, 1 sided · p = <0.0001 (P-value is computed by integrating on the p-values of one-sided test with alpha=0.025 and the posterior probability of the cut-off in the control group)
  • Hiberix Group vs ActHIB Group · t-test, 1 sided · p = <0.0001 (P-value is computed by integrating on the p-values of one-sided test with alpha=0.025 and the posterior probability of the cut-off in the control group)
PrimaryNumber of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off Value

The cut-off value was defined as a concentration ≥ 8 ED50 (ED50 is the concentration at which the protein exhibits 50% of its maximum activity). The polio testing which started at the Biomnis laboratory was stopped because the polio virus micro-neutralization assays were found to be not in line with the quality standards defined in GSK Biologicals' SOPs. As a result, polio testing was restarted at the GSK laboratory and the results were uploaded into the clinical database.

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off Value
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-Polio 1246181164
Anti-Polio 2275188183
Anti-Polio 3254181168
Statistical analysis
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: -0.67 · 97.5% CI -2.24 to 0.87
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: 0.45 · 97.5% CI -1.45 to 2.91
  • Hiberix Group vs ActHIB Group · Non-inferiority analysis · Difference in percentage: -0.66 · 97.5% CI -2.2 to 0.88
PrimaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL

Non-inferiority of a booster dose of Hiberix co-administered with Infanrix in subjects 15-18 months of age who received 3 primary vaccine doses of Hiberix to a booster dose of ActHIB co-administered with Infanrix in subjects of 15-18 months of age who received 3 primary vaccine doses of ActHIB in terms of immune response to PRP

Time frame:
At 1 month after booster vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL333231184
SecondaryAnti-protein-D (Anti-D) and Anti-protein-T (Anti-T) Antibody Concentrations

Antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as International Units per milliliter (IU/mL).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Geometric mean · IU/mL
Anti-protein-D (Anti-D) and Anti-protein-T (Anti-T) Antibody Concentrations
IU/mLHiberix GroupActHIB GroupPentacel Group
Anti-D2.72 (2.54 to 2.93)2.45 (2.24 to 2.68)1.88 (1.69 to 2.09)
Anti-T2.23 (2.07 to 2.41)2.44 (2.20 to 2.71)1.72 (1.55 to 1.91)
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.

Time frame:
During a 4-day follow-up period (Days 0-3) following any vaccination
Reported as:
Number · Subjects
Number of Subjects With Any Solicited Local Symptoms
SubjectsHiberix GroupActHIB GroupPentacel Group
Any pain1932366370
Any redness1165233257
Any swelling834174195
SecondaryNumber of Subjects With Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Rectal temperature equal to or above (≥) 38 degrees Celsius (°C).

Time frame:
During a 4-day follow-up period (Days 0-3) following any vaccination
Reported as:
Number · Subjects
Number of Subjects With Any Solicited General Symptoms
SubjectsHiberix GroupActHIB GroupPentacel Group
Any drowsiness2179398378
Any irritability2478449434
Any loss of appetite1450275253
Any fever1014186143
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs).

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day (Day 0-Day 30) follow-up period after primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Any Unsolicited Adverse Events (AEs).
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With Any Unsolicited Adverse Events (AEs).1880350324
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Day 0 until 6 months following the last primary dose
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs)
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With Serious Adverse Events (SAEs)1082421
SecondaryNumber of Subjects With AEs of Specific Interest (AESIs)

An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.

Time frame:
From Day 0 until 6 months following the last primary dose or the receipt of the booster vaccination, whichever comes first
Reported as:
Number · Subjects
Number of Subjects With AEs of Specific Interest (AESIs)
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With AEs of Specific Interest (AESIs)1082215
SecondaryNumber of Subjects With Seroresponse (90%) to Anti-PT, Anti-PRN and Anti-FHA

Seroresponse (90%) was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Seroresponse (90%) to Anti-PT, Anti-PRN and Anti-FHA
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-PT706248165
Anti-PRN741250194
Anti-FHA705248166
SecondaryNumber of Subjects With Anti-PT, Anti-PRN and Anti-FHA Antibody Concentrations ≥ 5 EL.U/mL

Seroresponse was defined as the number of subjects showing a concentration above a threshold that leads to 90% seroresponse in the ActHIB group.

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-PT, Anti-PRN and Anti-FHA Antibody Concentrations ≥ 5 EL.U/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-PT789275249
Anti-PRN786275244
Anti-FHA791275249
SecondaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL

Evaluation of persistence of anti-PRP antibodies induced by three primary vaccine doses of Hiberix, and ActHIB, each co-administered with Pediarix, Prevnar 13 and Rotarix, or Pentacel co-administered with Engerix-B, Rotarix and Prevnar 13 prior to the booster dose of Hiberix, ActHIB or Pentacel at 15-18 months of age and evaluation of immunogenicity of a booster dose of Hiberix co-administered with Infanrix, ActHIB co-administered with Infanrix and Pentacel in terms of the percentage of subjects with anti-PRP concentrations ≥0.15 µg/mL, ≥1.0 µg/mL and GMCs one month after the booster dose.

Time frame:
Prior to the booster vaccination and 1 month after the booster vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 0.15 µg/mL and ≥ 1.0 µg/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-PRP ≥ 0.15 µg/mL; PRE vaccination247172116
Anti-PRP ≥ 0.15 µg/mL; POST vaccination336235186
Anti-PRP ≥ 1 µg/mL; PRE vaccination1066144
Anti-PRP ≥ 1 µg/mL; POST vaccination333231184
SecondaryAnti-Hepatitis B (Anti-HBs) Antibody Concentrations

Antibody concentrations were tabulated as geometric mean concentrations (GMCs) and expressedas milli-international units per milliliter (mIU/mL).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Geometric mean · mIU/mL
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations
mIU/mLHiberix GroupActHIB GroupPentacel Group
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations3684.3 (3287.0 to 4129.5)3545.6 (3067.8 to 4098.0)1573.4 (1302.6 to 1900.6)
SecondaryNumber of Subjects With S.Pneumoniae Antibody Concentrations ≥ 0.05 µg/mL, ≥ 0.2 µg/mL and ≥1.0 µg/mL

Evaluation of immunogenicity of a 3-dose primary vaccination course of Prevnar 13 co-administered with Hiberix, Rotarix and Pediarix, of Prevnar 13 co-administered with ActHIB, Rotarix and Pediarix and of Prevnar 13 co-administered with Pentacel, Rotarix and Engerix-B in terms of S.pneumoniae GMCs and antibody concentrations ≥ 0.05µg/mL, ≥ 0.2 µg/mL, ≥ 1.0 µg/mL at one month after the last dose of primary vaccination.

Time frame:
At 1 month after the last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With S.Pneumoniae Antibody Concentrations ≥ 0.05 µg/mL, ≥ 0.2 µg/mL and ≥1.0 µg/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
≥ 0.05 µg/mL, Anti-Pneumoniae 1384268245
≥ 0.05 µg/mL, Anti-Pneumoniae 3382269243
≥ 0.05 µg/mL, Anti-Pneumoniae 4389268247
≥ 0.05 µg/mL, Anti-Pneumoniae 5379266246
≥ 0.05 µg/mL, Anti-Pneumoniae 6A381267244
≥ 0.05 µg/mL, Anti-Pneumoniae 6B378260241
≥ 0.05 µg/mL, Anti-Pneumoniae 7F386269246
≥ 0.05 µg/mL, Anti-Pneumoniae 9V385270246
≥ 0.05 µg/mL, Anti-Pneumoniae 14384267244
≥ 0.05 µg/mL, Anti-Pneumoniae 18C380267244
≥ 0.05 µg/mL, Anti-Pneumoniae 19A383265244
≥ 0.05 µg/mL, Anti-Pneumoniae 19F384268245
≥ 0.05 µg/mL, Anti-Pneumoniae 23F384267244
≥ 0.2 µg/mL, Anti-Pneumoniae 1382267244
≥ 0.2 µg/mL, Anti-Pneumoniae 3379268243
≥ 0.2 µg/mL, Anti-Pneumoniae 4389267247
≥ 0.2 µg/mL, Anti-Pneumoniae 5377265245
≥ 0.2 µg/mL, Anti-Pneumoniae 6A379265243
≥ 0.2 µg/mL, Anti-Pneumoniae 6B351242224
≥ 0.2 µg/mL, Anti-Pneumoniae 7F386269246
≥ 0.2 µg/mL, Anti-Pneumoniae 9V385269243
≥ 0.2 µg/mL, Anti-Pneumoniae 14381265241
≥ 0.2 µg/mL, Anti-Pneumoniae 18C377267244
≥ 0.2 µg/mL, Anti-Pneumoniae 19A379259235
≥ 0.2 µg/mL, Anti-Pneumoniae 19F383267244
≥ 0.2 µg/mL, Anti-Pneumoniae 23F376265231
≥ 1.0 µg/mL, Anti-Pneumoniae 1334239213
≥ 1.0 µg/mL, Anti-Pneumoniae 3188140138
≥ 1.0 µg/mL, Anti-Pneumoniae 4318226199
≥ 1.0 µg/mL, Anti-Pneumoniae 5354250225
≥ 1.0 µg/mL, Anti-Pneumoniae 6A357253229
≥ 1.0 µg/mL, Anti-Pneumoniae 6B232151117
≥ 1.0 µg/mL, Anti-Pneumoniae 7F379264239
≥ 1.0 µg/mL, Anti-Pneumoniae 9V338234203
≥ 1.0 µg/mL, Anti-Pneumoniae 14360250223
≥ 1.0 µg/mL, Anti-Pneumoniae 18C361256229
≥ 1.0 µg/mL, Anti-Pneumoniae 19A290200164
≥ 1.0 µg/mL, Anti-Pneumoniae 19F357254231
≥ 1.0 µg/mL, Anti-Pneumoniae 23F297208180
SecondaryAntibody Titers for Poliovirus Types 1, 2 and 3

Antibody titers were given as geometric mean titers(GMTs).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Geometric mean · Titers
Antibody Titers for Poliovirus Types 1, 2 and 3
TitersHiberix GroupActHIB GroupPentacel Group
Anti-Polio 1570.8 (509.2 to 639.8)620.9 (540.1 to 713.7)136.0 (114.7 to 161.1)
Anti-Polio 2471.8 (416.7 to 534.1)389.9 (337.3 to 450.6)210.9 (181.9 to 244.5)
Anti-Polio 3982.8 (870.1 to 1110.2)963.2 (843.7 to 1099.5)297.4 (253.3 to 349.1)
SecondaryNumber of Subjects With Anti-HBs Antibody Concentrations Greater Than or Equal to Cut-off Values

The cut-off values were defined as a concentration≥ 3.3 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).

Time frame:
At 1 month after last dose of primary vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-HBs Antibody Concentrations Greater Than or Equal to Cut-off Values
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-HBs≥ 3.3 mIU/ml362257239
Anti-HBs≥ 10 mIU/ml362257239
SecondaryAnti-polyribosylribitol Phosphate (PRP) Antibody Concentrations

Antibody concentrations were given as Geometric Mean Concentrations (GMCs) expressed in micrograms per milliliter (µg/mL).

Time frame:
Prior to the booster vaccination and 1 month after the booster vaccination
Reported as:
Geometric mean · µg/mL
Anti-polyribosylribitol Phosphate (PRP) Antibody Concentrations
µg/mLHiberix GroupActHIB GroupPentacel Group
PRE0.498 (0.422 to 0.588)0.467 (0.385 to 0.567)0.380 (0.299 to 0.484)
POST48.782 (42.000 to 56.659)40.293 (33.386 to 48.630)37.543 (30.535 to 46.158)
SecondaryAnti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL

Antibody concentrations were expressed as geometric mean concentrations (GMCs) and expressed as milli-international units per milliliter (mIU/mL).

Time frame:
Prior to the booster vaccination
Reported as:
Geometric mean · mIU/mL
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL
mIU/mLHiberix GroupActHIB GroupPentacel Group
Anti-Hepatitis B (Anti-HBs) Antibody Concentrations ≥10.0 mIU/mL and ≥6.2 mIU/mL268.3 (226.7 to 317.5)247.0 (199.8 to 305.3)156.4 (117.9 to 207.5)
SecondaryNumber of Subjects With Anti-HB Antibody Concentrations ≥10.0 mlU/mL and ≥6.2mLU/mL

The cut-off values were defined as a concentration≥ 6.2 mIU/mL (seropositivity) and ≥ 10 mIU/mL (seroprotection).

Time frame:
Prior to booster vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-HB Antibody Concentrations ≥10.0 mlU/mL and ≥6.2mLU/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-HBs ≥ 6.2 mIU/mL311199156
Anti-HBs ≥10.0 mIU/mL306198154
SecondaryNumber of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations ≥ 5 EL.U/mL

Evaluation of persistence of anti-PT, anti-FHA and anti-PRN antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-PT, anti-FHA and anti- PRN antibodies.

Time frame:
Prior to the booster vaccination and 1 month after the booster vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-PT, Anti-FHA and Anti-PRN Concentrations ≥ 5 EL.U/mL
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-FHA, PRE328223171
Anti-FHA, POST335235185
Anti-PRN, PRE279174130
Anti-PRN, POST331233185
Anti-PT, PRE24316881
Anti-PT, POST335235186
SecondaryAnti-poliovirus Types 1, 2, and 3 Antibody Titres and Titres ≥ 8

Antibody concentrations were tabulated as geometric mean titers (GMTs) and expressed as titers.

Time frame:
Prior to the booster vaccination
Reported as:
Geometric mean · Titers
Anti-poliovirus Types 1, 2, and 3 Antibody Titres and Titres ≥ 8
TitersHiberix GroupActHIB GroupPentacel Group
Anti-polio 1106.2 (91.1 to 123.8)101.6 (84.4 to 122.3)25.1 (20.3 to 31.0)
Anti-polio 2109.4 (92.8 to 129.1)89.5 (73.4 to 109.1)48.9 (39.7 to 60.2)
Anti-polio 3154.8 (129.3 to 185.3)151.9 (122.4 to 188.5)40.6 (31.4 to 52.5)
SecondaryNumber of Subjects With Anti-Polio-1,2,3 Antibody Titers ≥ 8

Anti-polio 1,2,3 antibody titers greater or equal to the cut off value were calculated.

Time frame:
Prior to booster vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-Polio-1,2,3 Antibody Titers ≥ 8
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-polio 1294197124
Anti-polio 2285196144
Anti-polio 3283201130
SecondaryNumber of Subjects With Anti-D and Anti-T Antibody Concentrations ≥ 0.1 IU/mL and ≥1.0 IU/mL, Respectively.

Evaluation of persistence of anti-D, anti-T antibodies induced by Pediarix or Pentacel and Engerix-B prior to the administration of a booster dose of Hib vaccine at 15-18 months of age and evaluation of immunogenicity of a booster dose of Infanrix co-administered with Hiberix, a booster dose of Infanrix co-administered with ActHIB and a booster dose of Pentacel with respect to anti-D and anti-T antibodies.

Time frame:
Prior to the booster vaccination and 1 month after the booster vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-D and Anti-T Antibody Concentrations ≥ 0.1 IU/mL and ≥1.0 IU/mL, Respectively.
SubjectsHiberix GroupActHIB GroupPentacel Group
Anti-D≥ 0.1 IU/mL, PRE322218173
Anti-D≥ 0.1 IU/mL, POST336236186
Anti-T≥ 0.1 IU/mL, PRE292196154
Anti-T≥ 0.1 IU/mL, POST336236186
Anti-D≥1.0 IU/mL , PRE1518970
Anti-D≥1.0 IU/mL , POST334234186
Anti-T≥1.0 IU/mL , PRE522714
Anti-T≥1.0 IU/mL , POST330233180
SecondaryNumber of Subjects With Any Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any symptom regardless of intensity grade.

Time frame:
Within 4 days (Days 0-3) following the booster dose
Reported as:
Number · Subjects
Number of Subjects With Any Solicited Local Symptoms
SubjectsHiberix GroupActHIB GroupPentacel Group
Any Pain918179163
Any Redness659127115
Any Swelling3928275
SecondaryNumber of Subjects With Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, irritability, fever and loss of appetite. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Any fever= Axillary temperature equal to or above (≥) 38 degrees Celsius (°C).

Time frame:
Within 4 days (Days 0-3) following the booster dose
Reported as:
Number · Subjects
Number of Subjects With Any Solicited General Symptoms
SubjectsHiberix GroupActHIB GroupPentacel Group
Any Drowsiness857164119
Any Irritability1293250201
Any Loss of appetite61414185
Any Fever1191820
SecondaryNumber of Subjects With AEs of Specific Interest (AESIs)

An AESI was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.

Time frame:
From booster dose until 6 months following receipt of the booster dose
Reported as:
Number · Subjects
Number of Subjects With AEs of Specific Interest (AESIs)
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With AEs of Specific Interest (AESIs)47127
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs).

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
Within 31 days (Day 0 to Day 30) following the booster dose
Reported as:
Number · Subjects
Number of Subjects With Any Unsolicited Adverse Events (AEs).
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With Any Unsolicited Adverse Events (AEs).882159138
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From the booster dose until 6 months following receipt of the booster dose
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs)
SubjectsHiberix GroupActHIB GroupPentacel Group
Number of Subjects With Serious Adverse Events (SAEs)2942
SecondaryAnti-FHA, Anti-PRN and Anti-PT Antibody Concentrations

Antibody concentrations were given as geometric mean concentrations (GMCs) expressed as enzyme-linked immuno-sorbent assay (ELISA) units per milliliter i.e. EL.U/mL.

Time frame:
pre-booster and one month after booster vaccination
Reported as:
Geometric mean · EL.U/mL
Anti-FHA, Anti-PRN and Anti-PT Antibody Concentrations
EL.U/mLHiberix GroupActHIB GroupPentacel Group
Anti-FHA, PRE41.3 (37.4 to 45.6)40.0 (35.2 to 45.5)22.7 (20.0 to 25.7)
Anti-FHA, POST464.9 (430.0 to 502.7)492.5 (449.0 to 540.3)263.8 (239.5 to 290.5)
Anti-PRN, PRE13.3 (12.0 to 14.8)11.2 (9.8 to 12.9)9.7 (8.3 to 11.3)
Anti-PRN, POST288.9 (260.4 to 320.5)259.2 (225.6 to 297.7)153.2 (128.5 to 182.6)
Anti-PT, PRE8.5 (7.7 to 9.3)8.6 (7.7 to 9.7)4.8 (4.2 to 5.3)
Anti-PT, POST90.9 (83.9 to 98.4)93.1 (84.1 to 103.1)75.3 (66.7 to 85.1)

Adverse events

Collected over SAEs= Day 0 to 6 months following last primary dose and from booster dose until 6 months after receipt of booster dose. Systematically and non-systematically assessed frequent AEs=within 4 and 31 days following primary and booster vaccination respectively. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hiberix Group—120/2,963 (4%)2,783/2,963 (93.9%)
ActHIB Group—24/520 (4.6%)495/520 (95.2%)
Pentacel Group—21/520 (4%)488/520 (93.8%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventHiberix GroupActHIB GroupPentacel Group
Respiratory syncytial virus bronchiolitisInfections and infestations13/29634/5202/520
DehydrationMetabolism and nutrition disorders10/29633/5201/520
Febrile convulsionNervous system disorders8/29633/5200/520
BronchiolitisInfections and infestations16/29632/5202/520
PneumoniaInfections and infestations14/29632/5202/520
Croup infectiousInfections and infestations4/29630/5202/520
Otitis mediaInfections and infestations10/29630/5202/520
Respiratory syncytial virus infectionInfections and infestations9/29632/5200/520
Subcutaneous abscessInfections and infestations3/29632/5200/520
Upper respiratory tract infectionInfections and infestations2/29632/5200/520
Most frequent other events
Showing 10 of 17
Most frequent other events
EventHiberix GroupActHIB GroupPentacel Group
IrritabilityPsychiatric disorders2525/2963459/520441/520
SomnolenceNervous system disorders2235/2963409/520387/520
PainGeneral disorders2035/2963380/520383/520
Decreased appetiteMetabolism and nutrition disorders1596/2963304/520272/520
ErythemaSkin and subcutaneous tissue disorders1306/2963262/520277/520
PyrexiaGeneral disorders1288/2963240/520201/520
SwellingGeneral disorders944/2963191/520211/520
Upper respiratory tract infectionInfections and infestations655/2963109/520105/520
CoughRespiratory, thoracic and mediastinal disorders369/296364/52073/520
Otitis mediaInfections and infestations355/296363/52061/520

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Hiberix GroupActHIB GroupPentacel GroupTotal
Mean8.6 ± 1.088.6 ± 1.138.7 ± 1.128.61 ± 1.09
Sex: Female, Male
Sex: Female, Male(Participants)Hiberix GroupActHIB GroupPentacel GroupTotal
Female14242712581953
Male15392492622050
08

Study locations

63 sites
  • GSK Investigational Site
    Dothan, Alabama 36305, United States
  • GSK Investigational Site
    Benton, Arkansas 72019, United States
  • GSK Investigational Site
    Fayetteville, Arkansas 72703, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Anaheim, California 92804, United States
  • GSK Investigational Site
    Antioch, California 94509, United States
  • GSK Investigational Site
    Daly City, California 94015, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Fremont, California 94538, United States
  • GSK Investigational Site
    Fresno, California 93726, United States
  • GSK Investigational Site
    Hayward, California 94545, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Oakland, California 94612, United States
  • GSK Investigational Site
    Redwood City, California 94063, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    Sacramento, California 95815, United States
  • GSK Investigational Site
    Sacramento, California 95823, United States
  • GSK Investigational Site
    San Jose, California 95119, United States
  • GSK Investigational Site
    Santa Clara, California 95051, United States
  • GSK Investigational Site
    Santa Rosa, California 95403, United States
  • GSK Investigational Site
    Vallejo, California 94589, United States
  • GSK Investigational Site
    Walnut Creek, California 94596, United States
  • GSK Investigational Site
    West Covina, California 91790, United States
  • GSK Investigational Site
    Boulder, Colorado 80304, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80922, United States
  • GSK Investigational Site
    Orange City, Florida 32763, United States
  • GSK Investigational Site
    Marietta, Georgia 30062, United States
  • GSK Investigational Site
    Woodstock, Georgia 30189, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96819, United States
  • GSK Investigational Site
    Waipio, Hawaii 96797, United States
  • GSK Investigational Site
    Nampa, Idaho 83686, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Louisville, Kentucky 40291, United States
  • GSK Investigational Site
    Fall River, Massachusetts 02721, United States
  • GSK Investigational Site
    Stevensville, Michigan 49127, United States
  • GSK Investigational Site
    Saint Paul, Minnesota 55108, United States
  • GSK Investigational Site
    Omaha, Nebraska 68131, United States
  • GSK Investigational Site
    Mineola, New York 11501, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Utica, New York 13502, United States
  • GSK Investigational Site
    Fargo, North Dakota 58103, United States
  • GSK Investigational Site
    Canton, Ohio 44718, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Cleveland, Ohio 44121, United States
  • GSK Investigational Site
    Dayton, Ohio 45406, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74107, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16505, United States
  • GSK Investigational Site
    Greenville, Pennsylvania 16125, United States
  • GSK Investigational Site
    Hermitage, Pennsylvania 16148, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Amarillo, Texas 79124, United States
  • GSK Investigational Site
    Fort Worth, Texas 76107, United States
  • GSK Investigational Site
    Houston, Texas 77055, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Bountiful, Utah 84010, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Roy, Utah 84067, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    South Jordan, Utah 84095, United States
  • GSK Investigational Site
    Syracuse, Utah 84075, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
09

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2011 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2009
First posted
Oct 23, 2009
Start
Jun 18, 2010
Primary completionActual
Nov 18, 2011
CompletionActual
Jul 17, 2013
Results first posted
Aug 19, 2013
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01000974
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 23, 2009
Start date
Jun 18, 2010
Primary completion
Nov 18, 2011
Completion
Jul 17, 2013
Results posted
Aug 19, 2013
Last update
Jul 12, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hiberix · Pediarix

Start the discussion